echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Comparison of the efficacy of the new crown vaccine in preventing infection and severe disease: Moderna > Pfizer/BioNTech > Sinopharm > Kexing

    Comparison of the efficacy of the new crown vaccine in preventing infection and severe disease: Moderna > Pfizer/BioNTech > Sinopharm > Kexing

    • Last Update: 2022-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, a study from Singapore compared Pfizer/BioNTech's Comirnaty, Moderna's Spikevax, Kexing's CoronaVac (Kerlefu), and Sinopharm's BBIBP-CorV (Zhongai Kewei) after vaccination in the real world.


    Among them, Comirnaty and Spikevax are mRNA vaccines, and Clarion and Zhongai Kewei are inactivated vaccines


    Currently, about 96% of Singapore's population has been vaccinated against COVID-19


    Based on the mRNA vaccine of Pfizer/BioNTech, the infection risk and severe risk after 2 doses of different new crown vaccines are shown in the figure


    The researchers said that assuming two doses of Comirnaty had a protection rate of 90% against severe COVID-19 cases, the protection rates of Spikevax, Clarifex, and Zhongai Kewei were 96%, 54%, and 84%, respectively


    Attached:

    Note: The original text has been deleted

    (Related research sources: https://academic.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.